CRISPR Corrects Duchenne-Causing Mutations

Using CRISPR-Cpf1 gene editing, researchers have fixed mutations that cause a form of muscular dystrophy in cultured human cardiomyocytes and a mouse model.

head shot of blond woman wearing glasses
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Cardiomyocytes from patients with Duchenne muscular dystrophy (DMD) corrected by CRISPR-Cpf1 reframing during stemness (right) show restored dystrophin expression (red), compared to uncorrected cells (left). SCIENCE ADVANCES, Y. ZHANG ET AL. Researchers have been studying the CRISPR-Cas9 gene-editing system as a potential therapeutic tool to modify or delete pathogenic sequences within the human genome. Now, using a more recently discovered system, CRISPR-Cpf1, researchers have demonstrated its utility in correcting disease-causing mutations within the human and mouse genomes. In a paper published today (April 12) in Science Advances, a team led by researchers at the University of Texas (UT) Southwestern Medical Center described how it corrected Duchenne muscular dystrophy (DMD)–causing mutations in patient-derived stem cells and in a mouse model of the disease. Cpf1-based gene editing was able to at least partially restore function in cultures heart muscle cells derived from a DMD patient. The work is a proof of the concept that CRISPR-Cpf1 gene editing could be further developed to correct other disease-causing mutations.

“The authors use CRISPR-Cfp1 to correct the Dmd mutation in vitro and ex vivo,” Harvard Stem Cell Institute’s Amy Wagers, who was not involved in the work, wrote in an email to The Scientist. “This study nicely adds to the repertoire of tools available for Dmd editing, showing that Cpf1—like Cas9 nucleases evaluated in prior studies—is also effective for targeting frame-disrupting mutations in Dmd.”

“This exciting work offers another gene-editing reagent that could potentially be used in clinical settings in the future,” said Renzhi Han, who studies the molecular mechanisms of muscular dystrophies at the Ohio State University Medical Center and also was not involved in the study.

DMD, a fatal X-linked disease that results in progressively weakened skeletal and heart muscles, is caused by ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • head shot of blond woman wearing glasses

    Anna Azvolinsky

    Anna Azvolinsky is a freelance science writer based in New York City.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio